The mission behind our company
Our mission is to leverage our unique platform technology and expertise to discover and develop novel small molecule therapies aimed at addressing serious unmet medical needs for patients suffering from autoimmune and inflammatory diseases.
Decades of experience
across several industries
selective and potent
to drug development
EydisBio is the first group to develop a highly selective,
orally bioavailable TAK1 inhibitor for the treatment of
autoimmune and inflammatory diseases. Utilizing our
highly innovative chemistry platform, we pride ourselves
on our ability to develop highly selective kinase inhibitors
towards various diseases.
PhD: President & Founder
“Protein kinases are generally recognized as valuable drug targets because of their roles in many human diseases. Yet, very few drugs targeting protein kinases have successfully made it through clinical trials.
Targeting genome-expressed protein kinases is incredibly difficult. The genome expresses over 450 distinct protein kinases, as well as over 2,000 other non-related proteins with similar ATP-binding properties to protein kinases.
EydisBio is currently developing a series of highly selective protein kinase inhibitors. Using our Universial Purinome Capture Platform (UPCP), a unique chemoproteomics platform that can define novel chemical scaffolds, EydisBio can identify the protein kinase of interest against the myriad of other proteins. We believe that dialing out off-target liabilities early in the discovery process leads to both better therapeutic outcomes and higher developmental success rates.
Currently, EydisBio is focused on targets involved in autoimmune and inflammatory diseases, as well as various immune-related cancers.”
Meet our team of experts
EydisBio is an industry-leading biotech comprised of outstanding scientists, business advisors, and financial consultants. We are dedicated to creating solutions for unmet medical needs through autoimmune and inflammatory drug discovery, preclinical development, and purine-based small molecule compound development.